Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLoans and Notes ReceivablesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShort-Term Debt issuances
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Short-Term Debt repayments (2016 - 2023)

Historic Short-Term Debt repayments for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 12 years, with Q2 2023 value amounting to $12.2 million.

  • Lifecore Biomedical, Inc. \De\'s Short-Term Debt repayments rose 2240.0% to $12.2 million in Q2 2023 from the same period last year, while for May 2023 it was $54.6 million, marking a year-over-year increase of 2386.93%. This contributed to the annual value of $146.7 million for FY2024, which is 16849.19% up from last year.
  • Latest data reveals that Lifecore Biomedical, Inc. \De\ reported Short-Term Debt repayments of $12.2 million as of Q2 2023, which was up 2240.0% from $41.6 million recorded in Q1 2023.
  • In the past 5 years, Lifecore Biomedical, Inc. \De\'s Short-Term Debt repayments registered a high of $95.0 million during Q1 2021, and its lowest value of $800000.0 during Q4 2022.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s median Short-Term Debt repayments value was $17.0 million (recorded in 2019), while the average stood at $22.1 million.
  • Its Short-Term Debt repayments has fluctuated over the past 5 years, first surged by 103333.33% in 2019, then plummeted by 9000.0% in 2022.
  • Quarter analysis of 5 years shows Lifecore Biomedical, Inc. \De\'s Short-Term Debt repayments stood at $37.0 million in 2019, then crashed by 86.49% to $5.0 million in 2020, then skyrocketed by 60.0% to $8.0 million in 2021, then crashed by 90.0% to $800000.0 in 2022, then soared by 1430.0% to $12.2 million in 2023.
  • Its Short-Term Debt repayments was $12.2 million in Q2 2023, compared to $41.6 million in Q1 2023 and $800000.0 in Q4 2022.